利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

31 条记录 (耗时 0.014 秒)

    Method of treating angiogenesis
    1.
    发明授权
    Method of treating angiogenesis 失效
    治疗血管发生的方法

    公开(公告)号：US06632797B2

    公开(公告)日：2003-10-14

    申请号：US09876637

    申请日：2001-06-07

    申请人： Matti Siren

    发明人： Matti Siren

    IPC分类号： A61K3170

    CPC分类号： A61K31/6615 ,  A61K31/663 ,  A61K31/7024

    摘要： The present invention relates to a method of treating angiogenesis in tumor conditions in a mammal suffering therefrom which comprises administering to a mammal in need thereof an effective amount of a cyclic compound selected from the group consisting of cyclopentane, cyclohexane, cycloheptane, monosaccharide, disaccharide, trisaccharide, tetrasaccharide, piperidine, tetrahydrothiopyran, 5-oxotetrahydrothiopyran, 5,5-dioxotetrahydrothiopyran, tetrahydroselenopyran, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, 5-oxotetrahydrothiophene, 5,5-dioxotetrahydrothiophene, tetrahydroselenophene, benzene, cumene, mesitylene, naphthalene and phenanthrene, in which said cyclic compound is substituted by at least three vicinal phosphorus containing radicals of the formula: The present application is also directed to the use of these compounds for treating inflammatory conditions, tissue repair conditions and/or infectious conditions in a mammal.

    摘要翻译： 本发明涉及一种治疗患有其中的哺乳动物的肿瘤病症中的血管发生的方法，其包括向有需要的哺乳动物施用有效量的选自环戊烷，环己烷，环庚烷，单糖，二糖， 四氢噻吩，四氢噻吩，吡咯烷，四氢噻吩，5-氧代四氢噻吩，5,5-二氧代四氢噻吩，四氢硒吩，苯，枯烯，均三甲苯，萘和菲，其中 所述环状化合物被至少三个具有下式的邻位含磷基团取代：本申请还涉及这些化合物用于治疗哺乳动物的炎性病症，组织修复条件和/或感染状况的用途。

    Method of treating inflammation with inositol triphosphate
    3.
    发明授权
    Method of treating inflammation with inositol triphosphate 失效
    用三磷酸肌醇治疗炎症的方法

    公开(公告)号：US5019566A

    公开(公告)日：1991-05-28

    申请号：US173985

    申请日：1988-03-28

    申请人： Matti Siren

    发明人： Matti Siren

    IPC分类号： A61K31/66 ,  A61K33/04 ,  A61P39/02

    CPC分类号： A61K31/66 ,  A61K33/04 ,  Y10S514/886

    摘要： A method of reducing the negative effect of cadmium or aluminum ion or free-radicals in body tissues and a method of preventing or alleviating certain diseases and conditions by administering to a human or an animal a pharmaceutical composition comprising an amount of at least one specific isomer of inositol triphosphate sufficient to obtain said prevention or alleviation.

    Method of treating inflammatory, tissue repair and infectious conditions
    6.
    发明授权
    Method of treating inflammatory, tissue repair and infectious conditions 失效
    治疗炎症，组织修复和感染状况的方法

    公开(公告)号：US06949517B1

    公开(公告)日：2005-09-27

    申请号：US10635951

    申请日：2003-08-07

    申请人： Matti Siren

    发明人： Matti Siren

    IPC分类号： A61K31/675 ,  A61K31/70

    CPC分类号： A61K31/675

    摘要： The present invention relates to a method of treating inflammatory, tissue repair and infectious conditions in a mammal suffering therefrom which comprises administering to a mammal in need thereof an effective amount of a cyclic compound selected from the group consisting of cyclopentane, cyclohexane, cycloheptane, monosaccharide, disaccharide, triaccharide, tetrasaccharide, piperidine, tetrahydrothiopyrian, 5-oxotetrahydrothiopyran, 5,5-dioxotetrahydrothiopyran, tetrahydroselenopyran, tetrahydrofuran, pyrrolidine, tetrahydrothiophene, 5-oxotetrahydrothiophere, 5,5-dioxotetrahydrothiophene, tetrahydroselenophene, benzene, cumene, mesitylene, naphthalene and phenanthrene, in which said cyclic compound is substituted by at least three vicinal phosphorus containing radicals of the formula:

    摘要翻译： 本发明涉及一种治疗患有炎症，组织修复和感染症状的方法，其包括向有需要的哺乳动物施用有效量的选自环戊烷，环己烷，环庚烷，单糖的环状化合物 ，二糖，三糖，四糖，哌啶，四氢噻喃，5-氧代四氢噻喃，5,5-二氧代四氢噻喃，四氢硒吡喃，四氢呋喃，吡咯烷，四氢噻吩，5-氧代四氢噻吩，5,5-二氧代四氢噻吩，四氢硒吩，苯，异丙基苯，均三甲苯，萘和菲 其中所述环状化合物被至少三个邻位含磷基团取代，所述基团含有下式：

    Inositol triphosphates
    9.
    发明授权
    Inositol triphosphates 失效
    肌醇三磷酸

    公开(公告)号：US4851560A

    公开(公告)日：1989-07-25

    申请号：US015699

    申请日：1987-02-17

    申请人： Matti Siren

    发明人： Matti Siren

    IPC分类号： A21D2/00 ,  A21D2/30 ,  A23B7/154 ,  A23G1/00 ,  A23G1/30 ,  A23G3/00 ,  A23G3/34 ,  A23L1/015 ,  A23L1/03 ,  A23L1/212 ,  A23L1/30 ,  A23L2/00 ,  A23L3/3553 ,  A61K8/00 ,  A61K8/60 ,  A61K8/64 ,  A61K8/66 ,  A61K8/73 ,  A61K8/97 ,  A61K8/99 ,  A61K31/66 ,  A61K47/22 ,  A61K47/24 ,  A61P3/00 ,  A61P3/06 ,  A61P3/08 ,  A61P7/02 ,  A61P9/00 ,  A61P9/10 ,  A61P29/00 ,  A61P39/02 ,  C07F9/117 ,  C07H11/04 ,  C09K15/32 ,  C12P9/00

    CPC分类号： C07F9/117 ,  A21D2/30 ,  A23B7/154 ,  A23L29/05 ,  A23L3/3553 ,  A61K31/66 ,  A61K47/24 ,  C12P9/00 ,  Y10S514/97

    摘要： The disclosure of the present invention is directed to an inositol triphosphate compound, useful as a pharmaceutical agent, having the structural formula ##STR1## where (a) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydrogen;(b) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydrogen;(c) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.11 are hydrogen;(d) three or R.sub.1, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;(e) three of R.sub.1, R.sub.3, R.sub.6, R.sub.8, R.sub.9 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.7, R.sub.10 and R.sub.11 are hydrogen;(f) three of R.sub.1, R.sub.3, R.sub.6, R.sub.7, R.sub.10 and R.sub.12 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.5, R.sub.8, R.sub.9 and R.sub.11 are hydrogen;(g) three of R.sub.1, R.sub.3, R.sub.5, R.sub.8, R.sub.10 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.7, R.sub.9 and R.sub.12 are hydrogen; or(h) three of R.sub.1, R.sub.3, R.sub.5, R.sub.7, R.sub.9 and R.sub.11 are hydroxyl and the remaining three are phosphate and R.sub.2, R.sub.4, R.sub.6, R.sub.8, R.sub.10 and R.sub.12 are hydrogen.